DDInter657 DDInter899
A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Epoprostenol {u} (Compound) resembles {v} (Compound) Dinoprost Tromethamine
Epoprostenol {u} (Compound) resembles {v} (Compound) Treprostinil
Epoprostenol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alprostadil
Epoprostenol {u} (Compound) binds {v} (Gene) P2RY12
Epoprostenol {u} (Compound) palliates {v} (Disease) systemic scleroderma
Epoprostenol {u} (Compound) is included by {v} (Pharmacologic Class) Vasodilation
Epoprostenol {u} (Compound) causes {v} (Side Effect) Hypoaesthesia
Epoprostenol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Capsicum
Epoprostenol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Digoxin
Epoprostenol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Plicamycin
Epoprostenol (Compound) resembles Dinoprost Tromethamine (Compound)
Epoprostenol (Compound) resembles Treprostinil (Compound)
Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Alprostadil
Epoprostenol (Compound) binds P2RY12 (Gene)
Epoprostenol (Compound) palliates systemic scleroderma (Disease)
Epoprostenol (Compound) is included by Vasodilation (Pharmacologic Class)
Epoprostenol (Compound) causes Hypoaesthesia (Side Effect)
Epoprostenol may cause a minor interaction that can limit clinical effects when taken with Capsicum
Epoprostenol may cause a minor interaction that can limit clinical effects when taken with Digoxin
Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Plicamycin